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Laboratory diagnostics in patients with a hematological malig-
nancy has three major applications: establishing the diagnosis,
prognostic classiﬁcation and evaluation of treatment effective-
ness.1,2 Immunophenotyping is currently recognized to provide
essential information for all three applications.2–9 Expression of
individual immunophenotypic markers was initially assessed by
microscopic techniques, but since the 90’s multiparameter ﬂow
cytometric immunophenotyping has become the technique of
choice, as it is the sole technique that fulﬁlls the requirements for
high speed, broad applicability at diagnosis and during follow-up,
and accurate focusing on the malignant cell population using
membrane-bound and intracellular proteins as targets.9–14 Despite
the objectivity of ﬂow cytometric measurements, ﬂow cytometry is
perceived as a technique that is highly dependent on
expertise and is regarded to have limited reproducibility in
multicenter studies.15–18 This probably relates to the increasing
number of antibodies and ﬂuorochromes that are used and the
corresponding progressively larger complexity of the multivariate
data analyses of both major and minor cell populations, together
with limited standardization of the laboratory procedures and
instrument settings. In this regard, the weakest points of
multiparameter ﬂow cytometry relate to: (i) the design of the
panels of markers to be applied, (ii) the evaluation of new versus
‘classical’ markers, (iii) the analysis of the data obtained from the
ﬂow cytometric measurements and (iv) interpretation of the
results. In addition, it is a technological ﬁeld that is continuously
evolving, but where many traditional procedures are still in use,
for example, for data analysis. Whereas industry invested
signiﬁcantly in developing and implementing further innovation
of the ﬂow cytometry instruments, the innovation in
immunophenotyping reagents and in software for analysis of
the progressively larger and complex data sets was much more
limited or virtually absent, particularly in the area of leukemia and
lymphoma typing.
Consequently, we concluded in 2005 that major innovations are
required to adequately advance the ﬁeld of ﬂow cytometric
immunophenotyping. Therefore, we initiated the European Union
(EU)-supported EuroFlow Consortium. The original objectives of
the EuroFlow Consortium were: the development and evaluation
of novel antibodies, the introduction of novel immunobead
technology, the development of novel ﬂow cytometry software
tools and data analysis approaches for recognition of complex
immunophenotypic patterns, and the design of novel multicolor
immunostaining protocols and carefully balanced antibody
panels. In this editorial, we critically comment on the most
relevant aspects of the EuroFlow activities through a series of
frequently asked questions from the ﬁeld.
WHAT IS THE EUROFLOW CONSORTIUM?
EuroFlow is an independent scientiﬁc consortium that aims
at innovation and standardization of ﬂow cytometric
immunophenotyping to further improve and progress diagnostic
patient care. The EuroFlow Consortium was formed in 2005 to
initiate the EU-FP6 funded EuroFlow project (LSHB-CT-2006-
018708), which started in April 2006. The group was initially
composed of 440 researchers from eight different public
university hospital-based institutions in eight distinct European
countries, and two small/medium enterprises (SMEs), with
complementary experience and knowledge in the ﬁeld of ﬂow
cytometry immunophenotyping of hematological malignancies
(Table 1, Figure 1). More recently, the EuroFlow Consortium has
become a Scientiﬁc Working Group of the European Hematology
Association and it has expanded to a total of 11 institutions in
Europe and America (Table 1, Figure 2). Whereas the EU-FP6
funded EuroFlow project required the active and crucial contribu-
tion of the two SMEs, they left the consortium per 2012 to retain
the full scientiﬁc independence of the EuroFlow Consortium.
In parallel, the scientiﬁc activities of the group have extended to
other clinical diagnostic areas in the format of well-deﬁned
workpackages and projects. This includes the development of
X8-color antibody panels for lymphocyte subset studies in blood
and bone marrow of patients suspected to have a primary
immunodeﬁciency (PID Workpackage). Consequently, several
additional afﬁliated participants are currently being included for
this new workpackage.
WHAT WERE THE INITIAL AIMS OF THE EUROFLOW PROJECT?
The general aims of the EuroFlow project were the development
and standardization of fast, accurate and highly sensitive ﬂow
cytometry approaches for diagnosis and (sub)classiﬁcation
of hematological malignancies, as well as for the evaluation of
treatment effectiveness during follow-up. In the ﬁrst 4 years
(2006–2010) activities were exclusively focused on the diagnosis
and (sub)classiﬁcation of hematological malignancies. Five speciﬁc
aims were addressed in this period: (1) to evaluate the utility of
new antibodies developed either by the EuroFlow members or
other institutions and companies, (2) to introduce novel ﬂow
cytometry immunobead assays for the detection of fusion proteins
to be used for characterization of acute leukemias, (3) to deﬁne
multicolor ﬂow cytometry protocols and comprehensive antibody
panels for the diagnosis and classiﬁcation of hematological
malignancies, (4) to create novel software tools for recognition
of complex immunophenotypic patterns and multivariate analysis
of ﬂow cytometric data and (5) to promote standardization of ﬂow
cytometric immunophenotyping.19
WHAT ARE THE CURRENT ACHIEVEMENTS OF THE EUROFLOW
CONSORTIUM?
After a period of 5 years, the EuroFlow Consortium has reached
most of its initial goals, a large part of the results obtained being
presented in this issue of the Leukemia journal. In this period,
8-color antibody protocols for the diagnosis and classiﬁcation
of hematological malignancies have been developed.20 Such
protocols consist of a sequential combination of (i) screening
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tubes adapted to address distinct clinical questions and speciﬁc
medical indications of immunophenotyping and (ii) multi-tube
panels for the diagnosis and classiﬁcation per disease category.
The development of the new 8-color protocols was paralleled
by a set of standard operating procedures (SOP)21 to assure
full technical standardization of multicolor ﬂow cytometry based
on 3-laser ﬂow cytometry instruments, selection of appropriate
ﬂuorochromes, standardization of instrument settings and
laboratory protocols, and detailed testing and comparison of
antibody clones and ﬂuorochrome-conjugated antibodies
from multiple companies.20 For this purpose, development and
implementation of new software tools for fast and easy handling
of large data ﬁles,22,23 combining multiple tubes and mapping of
leukemia samples against templates of normal and pathological
reference samples for fast multidimensional pattern recognition,23
appeared to be crucial. Finally, new antibody clones were
developed against carefully selected epitopes of proteins
involved in chromosomal translocations, to be used in immuno-
bead assays for detection of the most frequent fusion proteins in
acute leukemias and chronic myeloid leukemia (CML).24–26
Table 1. List of initial and current EuroFlow members
Initial EuroFlow members (April, 2006) Current EuroFlow members (January, 2012)
Institute Senior scientist Other participants Institute Senior scientist Other participants
Erasmus MC,
Rotterdam, NL
JJM van Dongen VHJ van der Velden, J te






VHJ van der Velden, AW
Langerak, J te Marvelde,




A Orfao JF San Miguel, J Almeida,
J Flores-Montero, MB Vidriales,
JJ Pe´rez-Mora´n, Q Lecrevisse
University of Salamanca,
ES
A Orfao JF San Miguel, J Almeida,
J Flores-Montero, MB Vidriales,
JJ Pe´rez-Mora´n, Q Lecrevisse
Dynomics,
Rotterdam, NL
F Weerkamp K Brouwer-de Cock Instituto Portugues de
Oncologia, Lisbon, PT




M Martı´n-Ayuso J Herna´ndez, M Mun˜oz,
J Bensado´n
University of Schleswig-
Holstein – Campus Kiel,
DE
M Kneba S Bo¨ttcher, M Ritgen, M
Bru¨ggemann, E Harbst, L Falck
Instituto Medicina
Molecular, Lisbon, PT
A Parreira P Lucio, M Gomes da Silva,
J Parreira, A Mendonc¸a
Hoˆpital Necker-Enfants
Malades, Paris FR





M Kneba S Bo¨ttcher, M Ritgen,
M Bru¨ggemann, V Krull
Charles University,
Prague, CZ
J Trka J Hrusak, T Kalina, E Mejstrikova,




E Macintyre L Lhermitte, V Asnafi Medical University of
Silesia, Zabrze, PL
T Szczepanski L Se˛dek, J Bulsa, A Sonsala
St James University
Hospital, Leeds, UK
S Richards AC Rawstron, PA Evans,
R de Tute, M Cullen
Federal University of Rio
de Janeiro, BR
CE Pedreira ES da Costa
Charles University,
Prague, CZ









T Szczepanski L Se˛dek University Hospital
Gasthuisberg, Leuven, BE
N Boeckx
University of Porto, PT M Lima AH Santos
Abbreviations: BE, Belgium; BR, Brazil; CZ, Czech Republic; DE, Germany; ES, Spain; FR, France; NL, The Netherlands; PL, Poland; PT, Portugal; UK, United
Kingdom.
Figure 1. EuroFlow members attending the first EuroFlow meeting held in Salamanca (April, 2006).
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WHY DID IT TAKE SEVERAL YEARS TO DEVELOP THE
EUROFLOW ANTIBODY PROTOCOLS?
With a few exceptions focused on speciﬁc diseases,27,28 most
antibody panels that have been proposed so far by consensus
groups consist of lists of markers with limited or no information
about reference clones or about the most adequate ﬂuorochrome
conjugates.9,17,29–34 Also no guidelines are provided on how such
markers should be combined in single-tube or multi-tube
multicolor antibody panels. The composition of such lists
of markers most frequently relies on ‘expert opinions’, based on
experience and knowledge shared during meetings that run for a
few days, where ‘consensus’ is reached by majority voting among
the experts. Consequently, agreement about the informative and
relevant markers is reached in a relatively fast way and the lists of
consensus markers can be rapidly transferred to the public
domain, for example, through one or more publications.9,17,29–34
As consensus recommendations are based on longstanding
experience of a major fraction of the group, markers with the
lowest CD numbers (for example, CD1 to CD50) are more likely to
be included as being informative, than the later deﬁned antibody
reagents (for example, CD100–CD400).17
During the ﬁrst two meetings of the EuroFlow group in 2006
(Table 2), a preliminary list of consensus markers was composed
for evaluation of informativity. The selected markers had to be
combined in panels and arranged in multicolor combinations that,
once applied to a given set of patient samples, would be capable
of answering speciﬁc clinical questions with an acceptable degree
of efﬁciency, greater than reached with the routinely applied
panels in the EuroFlow centers. In other words, they had to be
tested in parallel with the local panels, and their utility objectively
evaluated to prove their informativity and superiority over existing
panels. In practice, such evaluation of the preliminary consensus
panels showed a need for improvement for every antibody panel.
Consequently, this lead to multiple cycles (2–7) of (re)design and
(re)evaluation of the 8-color antibody panels, in which new
antibody clones and ﬂuorochrome conjugates were evaluated on
multiple cell samples per testing cycle.20 On top of this, we
carefully evaluated new (potentially informative) markers as well
as classical markers for their added value or redundancy in
the diagnosis and classiﬁcation of hematological malignancies.
The multiple cycles of antibody panel testing appeared very
demanding and required a lot of effort in terms of reagents,
personnel and logistics. This explains why the design of the
EuroFlow antibody panels took more than 3 years.
HOW WERE THE EUROFLOW ANTIBODY PANELS DESIGNED
AND TESTED?
The strategy used to design and test the different markers and
8-color combinations arranged in single tubes or multi-tube
panels that constitute the EuroFlow antibody panels are described
in detail in this issue of Leukemia.20 The design process followed
general rules and criteria. Overall two groups of markers were
selected to be combined in each multicolor staining: (i) markers
devoted to the identiﬁcation of distinct cell populations in a
sample (so-called backbone markers) and (ii) markers aimed at the
characterization of particular cell populations (characterization
markers). Backbone markers should efﬁciently identify both
normal and malignant cells of interest with a high sensitivity
and speciﬁcity. In multi-tube panels, backbone markers should be
placed at the same ﬂuorochrome position in every multicolor
antibody combination, to provide identical multidimensional
localization of the target cell population(s). If application of a
screening tube was envisaged in the diagnostic algorithm before a
multi-tube panel, the backbone markers of the screening tube
were arranged at the same ﬂuorochrome positions as in the
related multi-tube panel, whenever possible. Through such
strategy, automated gate setting for the deﬁnition of the target
cell population(s) becomes possible. At the same time, the
calculation procedures based on the nearest neighbor principle
allow generation of data ﬁles, where each cellular event contains
information about all parameters measured in the total set of
multicolor antibody combinations.22 In contrast to the backbone
markers, each characterization marker is present in only one tube
of a panel. Selection of characterization markers was based on
experience and knowledge from the literature about the
physiological role of the protein in normal cells, its expression
pattern and its clinical utility in immunophenotyping of leukemia
and lymphoma cells. For these markers, positioning in a speciﬁc
combination was evaluated with respect to the diagnostic utility
Figure 2. EuroFlow members attending the 19th EuroFlow meeting in Prague (October, 2011).
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of the combined markers. Each combination of backbone markers
and backbone plus characterization markers was objectively
evaluated using multivariate analysis strategies through the
Inﬁnicyt software (Cytognos SL, Salamanca, Spain).23 Based on
the results of the above described (re)design and (re)evaluation
strategy, characterization markers were included or excluded.
CAN THE EUROFLOW ANTIBODY PANELS BE USED IN ANY
FLOW CYTOMETER INSTRUMENT?
The EuroFlow panels were designed in such a way they would
work in all 3-laser ﬂow cytometry instruments, available at the
moment the project started in 2006 and capable of simulta-
neously reading X8 ﬂuorescence emissions, as described by
Kalina et al.21 However, by the end of 2009, new multi-color
instruments became commercially available.35 At that time, the
design of most antibody panels was completed or in an advanced
phase of testing. Consequently, it was not affordable for the
EuroFlow Consortium to restart the testing of the antibody panels
on the new instruments. However, the EuroFlow group is willing
to advise or guide such testing. This requires close collaboration
with the users and active involvement of the manufacturers of the
new instruments.
DO THE EUROFLOW PANELS CONTAIN ALL ‘CLASSICAL’ OR
WHO-RECOMMENDED ANTIBODIES?
The EuroFlow panels do contain virtually all ‘classical’ and
WHO-recommended markers,1,8,9,17,29,32,33,36,37 but some markers
were left out from, for example, the acute leukemia panels
(for example, CyCD22, CD11c and CyLysozyme) and the B-cell
chronic lymphoproliferative disorder (B-CLPD) panels (for example,
Table 2. Summary of EuroFlow meetings and their main topics addressed
City, Country Dates Main topics of meeting
1 Salamanca, ES 6–9 April 2006 Harmonization of informed consent forms and procedures
List of consensus markers for evaluation of informativity
Priority list of novel antibodies to be developed
Introduction to multicolor flow cytometry
Brainstorming on antibody protocols
2 Rotterdam, NL 20–23 September 2006 Standardization of instrument setup
Choices of fluorochromes for the antibody protocols
Introduction to Infinicyt software
Development of immunobead assays for fusion gene proteins
Preliminary proposals for backbone antibody testing per disease category
3 Prague, CZ 25–27 January 2007 First test results of BCR-ABL cytometric immunobead assay
Final proposal for fluorochrome choices
First proposals for choices of backbone markers
First design for ALOT and LST
4 Kiel, DE 28–30 June 2007 First testing results of ALOT and LST and proposal for adjustments
First design for PCD panel
Confirmation of backbone markers and first proposal for B-, T- and NK-CLPD panels
Final proposal for backbone markers for the AML/MDS and T-ALL panels
5 Lisbon, PT 22–24 November 2007 Fine tuning of ALOT, LST and PCD panels
New design of B-, T- and NK-CLPD panels
First testing results of BCP-ALL, T-ALL and AML/MDS panels and proposal for adjustment
6 Paris, FR 24–26 April 2008 Final proposals for the ALOT and PCD panels
Fine tuning of BCP-ALL, T-ALL, AML/MDS, T- and NK-CLPD panels
First results of standardization of immunostaining protocols
Final SOP for instrument settings and compensation
7 Roosendaal, NL 25–26 June 2008 First proposal for standardized immunostaining protocols
Ongoing testing of all panels
First results of the testing of the BCR-ABL RUO immunobead assay
8 Krako´w, PL 2–4 October 2008 First results of standardization of FCS and SSC scatter patterns
Ongoing testing of all panels
BCP-ALL and T-ALL panels ready to be used in prospective routine diagnostic testing versus
conventional onsite panels
9 Schiphol, NL 14–15 December 2008 Final proposal for B-CLPD panel
10 York, UK 11–13 February 2009 Final proposal for standard sample preparation protocol
Standard proposal for titration of antibodies
First design of SST panel
All other panels ready for collecting large series of samples for the EuroFlow database
Introduction of multivariate analysis of testing results using the Infinicyt software
PML-RARA immunobead assay ready for testing
11 Salamanca, ES 14–16 May 2009 Collection of samples for reference data files for the EuroFlow database for all panels
Final proposal for SST panel
Use of EuroFlow panels in routine diagnostics
12 Schiphol, NL 22–24 September 2009 Collection of samples for reference data files for the EuroFlow database for all panels
13 Lisbon, PT 14–16 January 2010 Collection of samples for reference data files for the EuroFlow database for all panels
14 Salamanca, ES 14–17 April 2010 Collection of samples for reference data files for the EuroFlow database for all panels
First design and testing of MRD panels for various disease categories
15 Hoofddorp, NL 13–15 October 2010 Collection of samples for reference data files for the EuroFlow database for all panels
First design and testing of MRD panels for various disease categories
16 Paris, FR 13–14 January 2011 Brainstorm meeting on ALL MRD panels
17 Lisbon, PT 20–21 January 2011 Brainstorm meeting on B-CLPD MRD panels
18 Leuven, BE 16–18 March 2011 Testing of adjusted MRD antibody panels for various disease categories
Collection of samples completed for most EuroFlow panels
19 Prague, CZ 5–7 October 2011 Discussion on final draft of EuroFlow Antibody Panel manuscript
Discussion on results of adjusted MRD antibody panels
20 Katowice, PL 21–23 March 2012 Discussion on results of adjusted MRD antibody panels
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ALOT, acute leukemia orientation tube; BCP, B-cell precursor; BE, Belgium;
CLPD, chronic lymphoproliferative disorder; CZ, Czech Republic; DE, Germany; ES, Spain; FR, France; FSC, forward scatter; LST, lymphoid screening tube; MDS,
myelodysplastic syndrome; MRD, minimal residual disease; NL, The Netherlands; PCD, plasma cell disorders; PL, Poland; PT, Portugal; RUO, research use only;
SOP, standard operating protocol; SSC, sideward scatter; UK, United Kingdom.
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FMC7). The deletion of these markers was based on their
redundancy or inferior information, when compared with the set
of other markers in the panel. As an example, markers like
CyLysozyme and CD11c were found to be inferior compared to
the combination of CD64, CD36, CD14 and CD300e (IREM-2)
together with the expression pattern of CD117 and HLADR, for
deﬁnition of early commitment to the monocytic lineage. Similarly,
FMC7 is known to recognize a speciﬁc epitope on the CD20
molecule38 and was found to be redundant and of no added value
to the selected combinations of markers in the B-CLPD multi-tube
antibody panel.
WHAT IS THE RELEVANCE OF THE NEW MARKERS IN THE
EUROFLOW ANTIBODY PANELS?
Selection of a given marker to be included in the EuroFlow
antibody panels was based on the type and quality of diagnostic
information provided in combination with the other markers of
the same panel. The contribution of the new markers is discussed
in detail in the sections of the EuroFlow antibody panel
manuscript.20 Nevertheless, we here provide some typical
examples. A ﬁrst example, is CD300e (IREM-2), which is currently
known to be speciﬁc for the monocytic lineage, being expressed
only at the later stages of maturation among CD14hi cells,39 and
thereby providing a powerful tool for the discrimination between
CD14þ monoblasts/promonocytes and more mature monocytic
cells. This may particularly be useful for the distinction between
acute monocytic leukemias (AML) and myeloproliferative/
myelodysplastic syndromes (MDS) like chronic myelomonocytic
leukemia. A second example is CD200, which was included in the
B-CLPD multi-tube antibody panel because of its added value in
the differential diagnosis between mantle cell lymphoma (typically
CD200 negative) and chronic lymphocytic leukemia (CLL) and
other CD200þ B-CLPD.40 A third example is CD305 (LAIR1),41 which
proved not only to be a reliable marker for hairy cell leukemia but
also to be particularly useful in other relevant differential diagnoses
of B-CLPD, such as CD10-negative follicular lymphomas. More
detailed information is provided by Bo¨ttcher et al.20 in Section 8 of
the EuroFlow Antibody Panel Report in this issue of Leukemia.
CAN THE SAME RESULTS BE OBTAINED WITH FEWER
MARKERS?
EuroFlow antibody panels20 seem to consist of an extremely large
list of reagents. However, it should be noted that such panels aim
at addressing most clinical questions where multiparameter ﬂow
cytometry immunophenotyping has proven to be of clinical utility
in the diagnosis and classiﬁcation of all different types of
hematological malignancies, including the (very) rare disease
entities.20 Some diagnostic questions might not apply in
individual laboratories and several antibody combinations are
not required to answer the most frequent diagnostic questions.
Consequently, appropriate algorithms can be built for sequential
usage of distinct antibody tubes in a multi-tube panel. For
example, the ﬁrst tube of the B-CLPD multi-tube panel together
with the lymphoid screening tube (LST) is sufﬁcient for differential
diagnosis of CLL from other B-CLPD.20 Similarly, the ﬁrst four tubes
of the AML/MDS panel will provide all required information for full
immunophenotypic characterization of the vast majority of AML
and MDS cases. Application of the other three tubes of the AML/
MDS panel is only needed in a minority of rare leukemias and
myeloid disorders (see Van der Velden et al., in Section 7 of the
EuroFlow Antibody Panel Report).20
Furthermore, not every marker might seem essential for the
diagnosis or classiﬁcation in each individual case, but it should be
noted that the combination of markers is essential in a group of
patients. A clear example is the need for both CD19 and CD20 as
backbone markers for the B-CLPD panel.20 If only CD19 would be
used, neoplastic B cells from a subgroup of B-CLPD (for example,
follicular lymphomas) would not be identiﬁed by the common
backbone;42 in turn, if only CD20 would be used, CLL cells would
frequently not be detected because of the low CD20
expression.42,43
Finally, T-CLPD and NK-CLPD are relatively rare diseases that can
be detected by the LST, but which are frequently further
characterized in specialized centers with a strong focus on these
disease categories.
Therefore, each section of the EuroFlow Antibody Panel Report
clearly explains the contribution of each marker and the
contribution of each tube to the diagnostic process, so that
individual laboratories can decide which tubes and panels are
relevant for their own diagnostic practice.20
CAN OTHER FLUOROCHROMES, ANTIBODY CLONES OR
ANTIBODY CONJUGATES BE USED?
The EuroFlow antibody panels have been designed with some
ﬂexibility. However, because of the need of full standardization
and reproducibility of the results, reference reagents were deﬁned
for each marker in each multicolor combination (www.euroﬂow.
org). The selection of a given reagent was based on its unique
staining pattern of well-deﬁned normal and aberrant cells.
Therefore, the quality of a reagent was not solely evaluated on
the basis of its brightness, but also on its discrimination potential
between different cell populations present in a sample.23 For
example, if the brightest ﬂuorochrome would have been selected
for the CD38 reagents in the plasma cell disorders antibody panel,
it would be virtually impossible to represent on scale
simultaneously the CD38hi plasma cells and the CD38 negative
cell populations coexisting in the same sample (see Flores-
Montero et al., in Section 1 of the EuroFlow Technical Report).21,28
Despite all the above, the presented reference reagents should
not be viewed as the sole exclusive reagents that can be used in
the EuroFlow antibody panels. In fact, reagents from different
manufacturers that are conjugated to highly comparable ﬂuoro-
chromes or that use other antibody clones might also be used
instead of the corresponding reference reagent, as long as
identical or very similar staining patterns are obtained in a series
of patient samples. If individual laboratories prefer to use
alternative antibody clones and/or ﬂuorochrome conjugates in
the EuroFlow protocols, the performance of these potentially
equivalent reagents and the complete new set of markers should
be tested against the reference reagents before their acceptance.
Consequently, usage of other ﬂuorochromes or antibody clones
and conjugates is possible after careful evaluation of their
performance against the available reference reagents, following
stringent criteria for the deﬁnition of comparable performances.
CAN ADAPTATIONS OR EXTENSIONS OF THE EUROFLOW
ANTIBODY PANELS BE EXPECTED?
The EuroFlow antibody panels clearly contribute to answer most
current clinical diagnostic questions regarding characterization of
hematological malignancies. However, we also identiﬁed some
diagnostic questions, which the currently used antibody panels
cannot fully answer. Therefore, we anticipate that further
improvements can be expected in the future. In turn, we also
anticipate that EuroFlow antibody panels can answer additional
(new) clinical diagnostic questions based on the introduction of
the new markers and new concepts.
EuroFlow antibody panels can be reproduced in any laboratory
with appropriate ﬂow cytometers and a large database of fully
characterized cases, such as those that have already been
acquired at the EuroFlow centers using these panels. It is therefore
easily possible to evaluate the added diagnostic utility of novel
markers by measuring such markers in addition to the original
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panel and subsequently apply multivariate analyses—for example,
principal component analysis (PCA)—to the standard panel plus
the proposed marker. If such marker is of added value, it would
rank highly for the proposed differential diagnosis.
DO THE EUROFLOW ANTIBODY PANELS REQUIRE USAGE
OF THE EUROFLOW SOP FOR INSTRUMENT SET-UP AND
THE NEW SOFTWARE TOOLS?
The EuroFlow antibody panels and tools are ﬂexible in terms of
how they can be applied, but optimal performance is achieved
when used in combination with the EuroFlow SOP for instrument
set-up and software tools.
In fact, the deliverables of the EuroFlow project can be seen as a
comprehensive set of novel tools that can be combined according
to the needs of different laboratories. Consequently, one may
choose to use the EuroFlow antibody panels20 together with
the EuroFlow instrument set-up, sample preparation and data
analysis procedures,21 including EuroFlow reference data
ﬁles and templates for fast multivariate recognition of complex
protein expression patterns of suspected cells in a sample.23
Alternatively, one might decide just to use some of the newly
proposed markers or some multicolor antibody combinations or
even only those disease-oriented panels that have immediate
utility in the routine diagnostic work of a laboratory. Similarly, the
new software tools may be implemented without using the panels
or the instrument set-up procedures may be selected to be used
alone.
The EuroFlow group has developed a broad set of new tools
that contribute to improve routine diagnostic work in the ﬁeld of
ﬂow cytometric immunophenotyping in general and of hemato-
logical malignancies in particular. Obviously, the complete
combination of the EuroFlow tools provides more added value
than one tool on its own. For example, if the EuroFlow antibody
panels are used without the new multidimensional data analysis
tools of the Inﬁnicyt software (and consequently without the sets
of reference data ﬁles), it will be difﬁcult to rapidly evaluate the
complex immunophenotypic proﬁle of the gated malignant cells.
On the other hand, the same software tools may be used to
objectively evaluate the diagnostic value of the local in-house
antibody panel in comparison with the EuroFlow antibody panel
for each disease category.
Software tools for the classiﬁcation of diseases using EuroFlow
reference databases and PCA can be used only if the investigator
strictly adheres to the EuroFlow SOP for staining and instrument
set-up and if the original EuroFlow panels (or a comprehensively
evaluated replacements) are used.
WHAT WOULD BE THE ADVANTAGES OF USING THE
EUROFLOW 8-COLOR PANELS AND PROTOCOLS?
Usage of the EuroFlow panels and protocols has multiple
advantages and only few limitations. The main advantage is that
many deliverables of the EuroFlow project did not exist before and
provide new opportunities for improved, more objective and
standardized ﬂow cytometric diagnosis and classiﬁcation of
hematological malignancies in individual laboratories around the
world. These EuroFlow deliverables include: (i) new highly
informative diagnostic markers, (ii) new marker combinations for
better characterization of speciﬁc populations of normal and
neoplastic cells in blood, bone marrow and other types of
samples, (iii) new antibody panels and algorithms objectively
evaluated for multiple diagnostic questions with well-deﬁned
performance and clinical utility, (iv) standardized instrument set-
up and sample preparation procedures proved to allow full intra-
and inter-laboratory comparisons, (v) new software tools for
reliable and reproducible multivariate analysis of complex
immunophenotypic patterns of both normal and aberrant cell
populations, (vi) new templates of multiparameter ﬂow cytometry
data from normal reference samples as well as leukemia/
lymphoma reference samples classiﬁed according to the WHO
2008 criteria1 (Table 3). These normal and malignant reference
samples can now be used for rapid comparative assessment of the
nature of suspected phenotypic proﬁles in individual patient
samples.23
If the EuroFlow antibody panels and protocols are fully adopted
by a signiﬁcant number of laboratories and linked to (inter)national
clinical treatment protocols, they will signiﬁcantly progress the ﬁeld
in terms of standardization, reproducibility and clinical impact.
WHAT DOES EUROFLOW STANDARDIZATION MEAN?
The EuroFlow Consortium believes that harmonization is not
sufﬁcient to progress the ﬁeld and to obtain truly comparable
Table 3. Main objectives and achievements of the EuroFlow project
Objectives
1. Development of novel antibodies, particularly against intracellular proteins, such as oncoproteins and newly defined classification markers, as
identified by gene expression profiling and molecular cytogenetic findings
2. Novel immunobead technology for fast and easy classification of acute leukemias via detection of oncogenic fusion proteins in cell lysates
3. Novel flow cytometry software for easy and fast handling and integration of list mode data files of multi-tube 8-color immunostainings and
for automated pattern recognition of novel, reactive/regenerating and malignant cell populations
4. Evaluation and selection of fluorochromes suited for 8-color flow cytometric immunostainings
5. Development of standardized procedures for instrument settings and immunostaining procedures to guarantee reliable interlaboratory
comparability of flow cytometric immunophenotyping
6. Design, standardization and clinical evaluation of novel 8-color immunostaining protocols for diagnosis and classification of hematopoietic
malignancies
7. Design, standardization and clinical evaluation of 8-color immunostaining protocols for assessment of treatment effectiveness via monitoring
the malignant cells during and after treatment
Achievements/deliverables
1. Development of new antibodies directed to oncogene proteins and tumor-associated markers
2. Novel immunobead assays for detection of fusion proteins
3. Novel software for integration of list mode data files and multivariate data analysis
4. Standardized procedures for instrument set-up and 8-color flow cytometry immunostaining optimized for immunophenotyping of leukemias
and lymphomas
5. New evaluated EuroFlow antibody panels for diagnosis and classification of leukemias and lymphomas
6. Educational program (EuroFlow workshopsa, web pageb and scientific publications)
aPlease see Table 4. bwww.euroflow.org.
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results among different laboratories. Therefore, full standardiza-
tion is required. The EuroFlow standardization includes: (i) usage
of comparable 3-laser X8-color ﬂow cytometers; (ii) selection of
appropriate and compatible ﬂuorochromes; (iii) full standardiza-
tion of instrument settings (for example, based on bead
standards); (iv) standardization of laboratory protocols and
immunostaining procedures (SOPs); (v) careful selection of optimal
reference antibody clones per marker/CD code; (vi) design of
combinations of multiple 8-color tubes; (vii) new multivariate
software tools for the comparison of reference data ﬁles for
speciﬁc diagnostic questions; (viii) recognition of normal subsets,
including deﬁnition of complete normal and regenerating
differentiation pathways, using the same immunostaining proto-
cols; and (ix) mapping of new patient samples against large
databases of earlier collected patient samples and normal/
regenerating differentiation pathways, analyzed with the same
immunostaining protocol in different diagnostic centers.
Noteworthy, these are diagnostic techniques that may inﬂuence
the treatment decision process and accordingly they must be
conducted or at least supervised by specialized and well-trained
personnel who has not only technical skills but also the ability and
knowledge to perform interpretation of the results according to
the state of the art in the diagnostic and clinical ﬁeld of
hematological malignancies.
HOW SHOULD THE IMMUNOBEAD ASSAYS FIT INTO THE
DIAGNOSTIC ALGORITHMS?
EuroFlow has developed several immunobead assays for fast ﬂow
cytometric detection of fusion proteins in lysates from leukemic
cells carrying speciﬁc chromosomal translocations.25 The
immunobead assay has been designed to be applied for rapid
and easy identiﬁcation of the most frequent subtypes of acute
leukemias associated with speciﬁc recurrent cytogenetic
translocations that result in a fusion gene and consequently in a
fusion protein.24–26 Therefore, the immunobead assay ﬁts with the
aim of (sub)classiﬁcation of acute leukemias at diagnosis.25 Once
an acute leukemia is diagnosed and the lineage of the suspected
blast cells has been assessed by use of the acute leukemia
orientation tube (for example, non-lymphoid versus T- or B
lymphoid, see Lhermitte and colleagues,20 in Section 1 of the
EuroFlow Antibody Panel Report), identiﬁcation of the relevant
fusion proteins may start, that is, PML-RARA versus AML1-ETO and
CBFB-MYH11 versus TEL-AML1, BCR-ABL, E2A-PBX1 and MLL-AF4 for
cases suspected of acute promyelocytic leukemia, AML and B-cell
precursor acute lymphoblastic leukemia, respectively. In addition,
detection of the BCR-ABL fusion protein may also be used for fast
diagnosis and conﬁrmation of CML.24 This type of immunobead
assay is particularly suited for centers where rapid molecular
detection of chromosomal translocations is not implemented or
routinely performed, but where a standard ﬂow cytometer is
readily available. The immunobead assay is fast (results are
obtained in a few hours) and easy to perform, and allows reliable
detection of the most relevant and common fusion proteins,
independently of the breakpoints involved. The assay may be
used in a multiplex format where each bead population is labeled
differently. Finally, the assay may be run in parallel to standard
immunophenotyping with the EuroFlow acute leukemia antibody
panels. This will save technician time.
WHY ARE SOME OF THE EUROFLOW DELIVERABLES LINKED TO
SPECIFIC COMPANIES?
In line with the EU-FP6 guidelines, the ‘Speciﬁc Targeted Research
Project’ (STREP) of the EuroFlow Consortium included two SMEs as
formal members of the Consortium. The two SMEs were involved
from the start of the project onwards in the development of
products that were not available in the market and that could be
used for the aims of the EuroFlow project. Logically, such novel
products were linked to the companies that actively participated
in their development. These products contained innovative
solutions from the individual members of the EuroFlow group.
Table 4. Summary of EuroFlow educational symposia and workshops
Number City, Country Date Workshop title
1 Berlin, DE 4 June 2009 Innovation in flow cytometry symposium: ‘Presentation of the latest results of the
EuroFlow EHA Scientific Working Group’, 14th EHA Congress
2 Paris, FR 28 October 2009 First EuroFlow Educational Workshop: ‘Atelier d’information EuroFlow’
3 Coimbra, PT 22 January 2010 Second EuroFlow Educational Workshop: ‘Ana´lise de dados da citometria.’
4 Rotterdam, NL 13 March 2010 Third EuroFlow Educational Workshop: ‘EuroFlow Antibody panels and Infinicyt
Software’
5 Salamanca, ES 16–17 April 2010 Fourth EuroFlow Educational Workshop
6 Barcelona, ES 10 June 2010 Innovation in flow cytometry
Symposium: ‘Presentation of the latest results of the EuroFlow EHA Scientific
Working Group’, 15th EHA Congress
7 Dublin, UK 26 November 2010 EuroFlow Educational Workshop in association with the Academy of Medical
Laboratory Sciences: ‘EuroFlow Antibody panels and Infinicyt Software’
8 Paris, FR 9 March 2011 Fifth EuroFlow Educational Symposium: ‘EuroFlow meets FranceFlow’
9 Coimbra, PT 31 March–1 April 2011 Sixth EuroFlow workshop: ‘Desenho e aplicac¸a˜o dos paineis Euroflow de
Sı´ndromes Linfoproliferativos Cro´nicos de Ce´lulas B e de Gamapatias
Monoclonais’
10 Cape Town, SA 13–14 April 2011 EuroFlow Infinicyt Workshop
11 St. Petersburg, RU 18 May 2011 EuroFlow session: ‘Modern approaches to the diagnosis of lymphoproliferative
diseases’
12 Buenos Aires, AR 30 May–1 June 2011 ‘Curso Avanzado de Actualizacio´n en Onco-Hematologı´a por Citometrı´a de Flujo’
13 London, UK 9 June 2011 Innovation in flow cytometry symposium: ‘Presentation of the latest results of the
EuroFlow EHA Scientific Working Group’, 16th EHA Congress
14 Rio de Janeiro, BR 25–27 August 2011 1o Workshop do Conso´rcio EuroFlow no Rio de Janeiro
15 Prague, CZ 8 October 2011 Seventh EuroFlow Educational Symposium and Workshop
16 Katowice, PL 24 March 2012 Eighth EuroFlow Educational Symposium and Workshop
Abbreviations: AR, Argentina; BR, Brazil; CZ, Czech Republic; DE, Germany; EHA, European hematology association; ES, Spain; FR, France; NL, The Netherlands;
PL, Poland; PT, Portugal; RU, Russia; SA, South Africa; UK, United Kingdom.
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The SME Cytognos SL particularly worked in the innovations of the
Inﬁnicyt software tools, which are now commercially available. The
SME Dynomics (Rotterdam, The Netherlands) focused on the
development of new antibodies particularly for the immunobead
assay for detection of fusion proteins. The immunobead
technology has been transferred by Dynomics to BD Biosciences
(San Jose, CA, USA) for commercialization. The BCR-ABL immuno-
bead assay24 was launched in Autumn 2008 and the other
immunobead assays will follow soon, such as the PML-RARA
immunobead assay.26
EuroFlow is a consortium of scientiﬁc institutes and does not
have production facilities or a distribution network for products
related to its activities. However, to achieve production and
distribution of the novel products and make the public investment
money return into public (research) activities, the EuroFlow
Consortium Agreement (signed by all parties) indicated that
intellectual property derived from the deliverables of the EuroFlow
project should be patented, and licensed to commercial
companies that might be interested in large-scale (quality-
controlled) production and distribution of the EuroFlow deliver-
ables for rapid availability to the ﬁeld. In parallel, all institutions
and individual EuroFlow members declined their rights on
revenues (such as royalty rights) in favor of the EuroFlow
Consortium, to provide sustainability for future activities
and projects of the group, including Educational Workshops and
Educational Symposia (Table 4).
WHICH EUROFLOW ACTIVITIES ARE STILL ONGOING?
The current activities of the EuroFlow Consortium concern:
(1) Building the reference databases and templates for the whole
set of EuroFlow antibody panels to be linked to the software
tools (Inﬁnicyt software) that are already available.
(2) Design of innovative strategies for the detection of minimal
residual disease (MRD) during and after therapy in patients
that have reached complete remission according to conven-
tional criteria. The new strategies search for disease-oriented
single-tube combinations instead of patient-speciﬁc multicolor
antibody panels. This new MRD strategy takes advantage of all
new data analysis software tools and reference databases
collected previously.
(3) Because of the successful innovation and standardization in
the hemato–oncology ﬁeld, the EuroFlow Consortium has now
decided to extend its activities to ﬂow cytometric diagnosis
for other diseases such as primary immunodeﬁciencies. In this
context, more detailed studies on normal lymphocyte subsets
are being performed. These studies show that more than eight
colors might be needed to fully unravel all relevant B- and
T-cell subsets and their memory and effector pathways.
CONCLUSION: EUROFLOW TOOLS FOR COMPANION
DIAGNOSTICS IN PERSONALIZED MEDICINE
In the current era of personalized medicine, many different new
treatment options are being evaluated to further improve
treatment outcome while increasing quality of life, such as
treatment with antibodies and small (blocking) molecules. The
implementation and evaluation of such new treatment modalities
requires accurate diagnosis and classiﬁcation of the disease and
careful monitoring of treatment effectiveness. Consequently, the
applied diagnostics should be optimally suited for the manage-
ment of the involved patients. Such companion diagnostics is
currently particularly needed for patients with a hematological
malignancy, because the ﬁeld of hemato–oncology is ahead of the
other ﬁelds in medicine.
The EuroFlow antibody panels and technical protocols have
been developed for application as companion diagnostics for
(inter)national clinical treatment protocols, where standardization
and reproducibility are of utmost importance. In this way, the
EuroFlow achievements can contribute to advanced comparability
of innovative clinical treatment protocols and thereby to further
improvement of diagnostic and therapeutic patient care.
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